

8

Glossary

8.1	Management Confirmations	328
8.2	Definitions	329

8 Glossary

8.1 Management Confirmations

With due regard to best practice provision 1.4.3 of the DCGC, we confirm that:

- i. the report of the board of directors provides sufficient insights into any deficiency in the effectiveness of the internal risk management and control systems, as is further substantiated in Section 2 "Risk Factors" and Section 3 "Corporate Governance". The Audit and Compliance Committee executes the oversight with respect to management's implementation and substantiation of DCGC.
- ii. the internal risk and control systems described herein, particularly in paragraph 3.9.5 "Financial Risks and Controls" provide reasonable assurance that the financial reporting does not contain any material inaccuracies;
- iii. the internal risk and control systems provide limited assurance that sustainability reporting is free from material misstatements;
- iv. in light of and as set out in this report, while the company seeks to control operational and compliance risks in the manner and to the extent as described in this report, the Board is not aware that our internal risk management and control systems, would not provide sufficient comfort¹⁾ that the material operational and compliance risks faced by the company are effectively controlled in line with the risk appetite as of December 31, 2025;
- v. we confirm that we expect that our existing cash and cash equivalents and current financial assets will enable us to fund our operating expenses and capital expenditure requirements through at least the next 12 months. On the basis of the current state of affairs, it is justified that the financial reporting is prepared on a going concern basis; and
- vi. the report of the board of directors, particularly Section 2 "Risk Factors" includes the material risks, as referred to in best practice provision 1.2.1 of the DCGC as well as uncertainties, to the extent that they are relevant for our continuity for a period of 12 months after the preparation of this Annual Report. The aforementioned statement does not in any way limit the relevance or applicability of the Risk Factors set out in this Annual Report to the aforementioned period of 12 months.

1) Sufficient comfort is to be read as: comfort considering our risk appetite, the complexity of our enterprise, inherent limitations to these systems and other disclosures on these systems in our board report.

8.2 Definitions

The following explanations are intended to assist the general reader to understand certain terms used in this Annual Report. The definitions set out below apply throughout this Annual Report, unless the context requires otherwise.

Term	Definition
2021 Remuneration Policy	the Company's 2021 remuneration policy
2025 Extraordinary General Meeting	the extraordinary General Meeting held on November 18, 2025
2025 20-F	Form 20-F for the year ended December 31, 2025
2025 General Meeting	the AGM held on May 27, 2025
2025 Remuneration Policy	the Company's 2025 remuneration policy, which was adopted at the 2025 Extraordinary General Meeting
2025 Remuneration Report	the Company's 2025 remuneration report and compensation statement
2026 General Meeting	the AGM to be held on May 6, 2026
AAV	ANCA-associated vasculitis
AbbVie	AbbVie, Inc.
AbbVie Collaboration Agreement	the collaboration agreement with AbbVie, Inc. to develop and commercialize ARGX-115 (ABBV-151) as a cancer immunotherapy against the novel target GARP
ACA	the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010
AChR	anti-acetylcholine receptor
AChR-AB+	AChR antibody positive
ADSS	American depository shares
AFM	the Dutch Authority for the Financial Markets (Stichting Autoriteit Financiële Markten)
AGM	annual general meeting
AI Act	Regulation (EU) 2024/1689
AIM	autoimmune inflammatory myopathies
AKS	the U.S. federal Anti-Kickback Statute
AML	acute myleoid leukemia
AMP	average manufacturer price
AMR	antibody-mediated rejection
Annual Report	this annual report
argenx or the Company	argenx SE
Articles of Association	our current articles of association
ASyS	anti-synthetase syndrome
Audit and Compliance Committee	the audit and compliance committee of the Board of Directors
B-cell	B-lymphocyte
BCCA	Belgian Code on Companies and Associations
Bilateral Shareholders and Stakeholders Contacts Policy	our policy on bilateral contacts and dialogue with shareholders and stakeholders
BITC	Belgian Income Tax Code
BLA	biologics license application
Board By-Laws	the rules adopted by our Board of Directors that describe the procedure for holding meetings of the Board of Directors, for the decision-making by the Board of Directors and the Board of Directors' operating procedures
Board of Directors	consisting of our Executive Director(s) and our Non-Executive Directors.
BPCIA	the U.S. Biologics Price Competition and Innovation Act
Broteio	Broteio Pharma B.V.
C2	complement 2
CapEx	capital expenditure
CBAs	collective bargaining agreement
CEO	chief executive officer

Term	Definition
CFO	chief financial officer
cGMPs	current good manufacturing practices
CHMP	Committee for Medicinal Products for Human Use
CIDP	chronic inflammatory demyelinating polyneuropathy
Climate Delegated Act	Commission Delegated Regulation (EU) 2021/2139 of June, 4 2021 supplementing Regulation (EU) 2020/852 of the European Parliament and of the Council by establishing the technical screening criteria for determining the conditions under which an economic activity qualifies as contributing substantially to climate change mitigation or climate change adaptation and for determining whether that economic activity causes no significant harm to any of the other environmental objectives
CMC	Chemistry, Manufacturing and Controls
CMIP	Coupled Model Intercomparison Project
CMMI	Center for Medicare and Medicaid Innovation authority
CMOs	contract manufacturing organizations
CMS	Congenital myasthenic syndrome or Centers for Medicare & Medicaid, as the context dictates
Code of Conduct	our Code of Business Conduct and Ethics
Conditions for the Application of the Dividend Received Deduction Regime	(i) the Belgian resident company holds (A) ADSs representing at least 10% of our share capital or (B) a participation with an acquisition value of at least €2,500,000 which (unless the shareholder is a Small Company) qualifies as “fixed financial asset” (financiële vaste activa). The condition relating to the qualification as “fixed financial asset” applies as of assessment year 2026; (ii) the ADSs representing our share capital have been or will be held in full ownership for an uninterrupted period of at least one year; and (iii) the conditions described in Article 203 of the BITC (relating to the taxation of the underlying distributed income and the absence of abuse), are met
COO	chief operating officer
COSO	Committee of Sponsoring Organizations of the Treadway Commission
CRO	contract research organization
CREATES	the Creating and Restoring Equal Access to Equivalent Samples
CSRD	Directive (EU) 2022/2464 of the European Parliament and of the Council of December, 14 2022 amending Regulation (EU) No 537/2014, Directive 2004/109/EC, Directive 2006/43/EC and Directive 2013/34/EU, as regards corporate sustainability reporting
CTA	clinical trial application
CTD	Clinical Trials Directive 2001/20/EC
CTR	EU Regulation No 536/2014 of the European Parliament and of the Council of April, 16 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (clinical trials regulation)
DCC	Dutch Civil Code (Burgerlijk Wetboek)
DCGC	the Dutch Corporate Governance Code 2025
DEFRA	Department for Environment, Food and Rural Affairs
Deloitte	Deloitte Accountants B.V.
DFSA	Dutch Financial Supervision Act (Wet op het financieel toezicht)
DGF	delayed graft function
DHS	dehydrated hereditary stomatocytosis
Digital Technology	Digital Technology function, previously known as Business Information System (BIS), is our all-encompassing IT division; driving innovation through data, AI, and strategic partnerships
Dividend Received Deduction	deduction of 100% of the gross dividend received from taxable income
DM	dermatomyositis
DMA	double materiality assessment
E&C	Ethics & Compliance
EFGCP	European Forum for Good Clinical Practice
e-Privacy Directive	Directive 2002/58/EC of the European Parliament and of the Council of July 12, 2002
ECL	expected credit loss
EEA	European Economic Area
EEIO	Environmentally Extended Input-Output

Term	Definition
EMA	European Medicines Authority
ENHANZE®	ENHANZE technology
ENHANZE® License Agreement	in-license agreement with Halozyme, Inc.
Enterprise Chamber	the Dutch Enterprise Chamber of the Amsterdam Court of Appeal (Ondernemingskamer van het Gerechtshof te Amsterdam)
Environmental Delegated Act	Delegated Regulation (EU) 2023/2486 of June 27, 2023
EPA	U.S. Environmental Protection Agency
EPS	Profit or loss per share
Equity Incentive Plan	the equity incentive plan as adopted by our Board of Directors on December 18, 2014, which was approved by the General Meeting on May 13, 2015, and amended by the General Meeting on April 28, 2016, and November 25, 2019, and the Board of Directors on December 18, 2019, November 5, 2020, December 15, 2021, on February 27, 2023, on February 28, 2024, on 30 June 2025 and on 4 March 2026
ERM	Enterprise Risk Management
ESG	environmental, social and corporate governance
ESRS	European Sustainability Reporting Standards
EU	European Union
EU-IFRS	IFRS® Accounting Standards (IFRS) as issued by the IASB and adopted by the EU
EU Pharmaceutical Legislation	Regulations (EC) No. 726/2004, No. 141/2000, or No. 1901/2006
EU Taxonomy Regulation	Regulation (EU) 2020/852 of the European Parliament and of the Council of June 18, 2020 on the establishment of a framework to facilitate sustainable investment, and amending Regulation (EU) 2019/2088
Euronext Brussels	the regulated market operated by Euronext Brussels SA/NV, a regulated market within the meaning of Directive 2014/65/EU of the European Parliament and of the Council of May 15, 2014, on markets in financial instruments amending Council Directives 2004/39/EC, Directive 85/611/EEC, 93/6/EEC and Directive 2000/12/EC of the European Parliament and of the Council and repealing Council Directive 93/22/EEC (MiFID II)
Exchange Act	the U.S. Securities Exchange Act of 1934, as amended
Executive Director	an executive director in the Board of Directors
EY	EY Accountants B.V.
Fc	antibody region interacting with cell surface Fc receptors
FCP	Federal Ceiling Price
FcRn	neonatal Fc receptor
FDA	U.S. Food and Drug Administration
FDCA	the U.S. Federal Food, Drug, and Cosmetic Act
FDORA	Food and Drug Omnibus Reform Act
FSS	Federal Supply Schedule
Fujifilm	FUJIFILM Diosynth Biotechnologies Denmark ApS
GARP	glycoprotein A repetitions predominant
GCPs	good clinical practices
GDPR	Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016, on the protection of natural persons with regard to the processing of personal data and on the free movement of such data
General Meeting	any general meeting of shareholders of argenx SE (i.e., any annual general meeting and any extraordinary general meeting)
GENEROUS	GENERating cost Reductions fOr U.S. Medicaid
GHG	greenhouse gas emissions
GLOBE	Global Benchmark for Efficient Drug Pricing
GLPs	good laboratory practices
gMG	generalized myasthenia gravis
GMP	good manufacturing practice
Greater China	Mainland China, Hong Kong, Taiwan and Macau
Group	argenx SE together with its subsidiaries
GUARD	Guarding U.S. Medicare Against Rising Drug Costs

Term	Definition
Halozyme	Halozyme Therapeutics, Inc.
Hatch-Waxman Act	the U.S. Drug Price Competition and Patent Term Restoration Act of 1984
HHS	U.S. Department of Health and Human Services
HIPAA	the U.S. federal Health Insurance Portability and Accountability Act of 1996
HITECH	Health Information Technology for Economic and Clinical Health Act of 2009
IASB	International Accounting Standards Board
IEA	International Energy Agency
IFRS	IFRS® Accounting Standards
IgA	Immunoglobulin A
IgG	Immunoglobulin G
IgM	Immunoglobulin M
IIP	immunology innovation program
IMM	irreversible morbidity or mortality
IMNM	immune-mediated necrotizing myopathy
IND	investigational new drug
IPCC	Intergovernmental Panel on Climate Change
IRA	Inflation Reduction Act
IRB	institutional review board
IROs	impacts, risks, and opportunities
ISAE	International Standard on Assurance Engagements
ISMS	Information Security and Management System
ITP	immune thrombocytopenia
IV	intravenous
IVIg	intravenous IgG
KPI	key performance indicator
LEI	European legal entity identifier number
Lonza	Lonza Sales AG
LTIP	Long term incentive plan
MA	marketing authorization
MAA	marketing authorization application
mAb	monoclonal antibody
MAH	marketing authorization holder
Mainland China	mainland China
MAR	Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/EC and 2004/72/EC, and the rules and regulations promulgated pursuant thereto
MFN	most favored nation
MG	myasthenia gravis
MG-ADL	Myasthenia Gravis Activities of Daily Living
MHLW	Ministry of Health, Labour and Welfare
MMN	multifocal motor neuropathy
MN	membranous nephropathy
MSE	minimal symptom expression
MuSK	muscle-specific kinase
Myositis	idiopathic inflammatory myopathies
Nasdaq	the Nasdaq Global Select Market
Nasdaq Listing Rules	the listing rules of the Nasdaq Global Market
NDA	new drug application
NEO	named executive officer
New Capital Gains Tax	the capital gains tax on financial assets (such as the ADSs) for capital gains realized as from January 1, 2026 as agreed to be introduced by the Belgian federal government
new Product Liability Directive	Directive (EU) 2024/2853

Term	Definition
NFRD	Directive 2014/95/EU of the European Parliament and the Council of 22 October 2014 amending Directive 2013/34/EU as regards disclosure of non-financial and diversity information by certain large undertakings and groups
NHI	National Health Insurance
NIS2	Directive (EU) 2022/2555 on Network and Information Security
NMJ	neuro muscular junction
Non-Executive Director	a non-executive director in the Board of Directors
Non-FAMP	Non-Federal Average Manufacturer Price
NRDL	National Reimbursement Drug List
OncoVerity	OncoVerity, Inc
OCI	other comprehensive income
Ocular MG	ocular myasthenia gravis
OFPs	organizations for financing pensions
OLE	open-label extension
OpEx	operating expenditure
PAA	pre-approval access program
PD	pharmacodynamic
PDUFA	Prescription Drug User Fee Act
PFIC	passive foreign investment company
PFS	prefilled syringe
PG&S	Purchased Goods and Services
Pharmaceutical and Medical Devices Act	the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices
PHSA	the U.S. Public Health Service Act
PIL Code	Belgian Code of private international law
Pillar Two	the project, worked on by the OECD in recent years, aimed at reforming the international tax system by, among other matters ensuring large multinational enterprises pay a minimum level of tax in each of the jurisdictions in which they operate
Pillar Two Directive	Directive (EU) 2022/2523 on ensuring a global minimum level of taxation for multinational enterprise groups and large-scale domestic groups in the Union
PK	pharmacokinetic
PMDA	Pharmaceuticals and Medical Devices Agency (Japan)
POC	proof-of-concept
PREA	Pediatric Research Equity Act of 2003, as amended
PSP	Pediatric Study Plan
PSU	performance share unit
PTA	Post-Trial Access
Relevant Regulatory Authorities	the MHRA, EMA, FDA, MHLW
Reference Date	30 calendar days preceding the 15th day of the month in which the grant of stock option occurs
Remuneration and Nomination Committee	remuneration and nomination committee of the Board of Directors
REMS	risk evaluation and mitigation strategy
RSU	restricted stock unit
R&D	research & development
SAAR	specific anti-abuse rule
SASB	Sustainability Accounting Standards Board
SBTi	Science Based Targets initiative
SC	subcutaneous
SEC	the U.S. Securities and Exchange Commission
Securities Act	the U.S. Securities Act of 1933, as amended
Senior Management Team	the Company's senior management team consisting of our CEO and senior personnel reporting directly to the CEO
Seronegative gMG	Seronegative generalized myasthenia gravis
Significant Stake	a participation of at least 20% in the company whose shares are being transferred

Term	Definition
SjD	sjögren's disease
SMA	spinal muscular atrophy
Small Company	a small company (kleine vennootschap), being a company that, on the balance sheet date of the last completed financial year, has not exceeded more than one of the following thresholds on a consolidated basis for two consecutive financial years: (i) an average annual number of 50 employees, (ii) an annual turnover excluding VAT of EUR 11,250,000 and (iii) a balance sheet total of €6,000,000 (cf. Article 2, §1,5°, c)bis of the BITC in conjunction with Article 1:24, §1 to §6 of the BCCA
Societas Europaea or SE	a Dutch European public company with limited liability
Taxonomy Regulation	Regulation (EU) 2020/852
TCFD	Task Force on Climate-related Financial Disclosures
TED	thyroid eye disease
third-party partner	includes suppliers and contractors
TIS	total improvement score
Transparency Directive	Directive 2004/109/EC of the European Parliament and of the Council of December 15, 2004, on the harmonization of transparency requirements in relation to information about issuers whose securities are admitted to trading on a regulated market and amending Directive 2001/34/EC and the rules and regulations promulgated pursuant thereto, as amended by various directives including 2013/50/EU
TTW	tank-to-wheel
UCHealth	University of Colorado Health
UCL	Université Catholique de Louvain
UK	the United Kingdom
UNGPs	UN Guiding Principles on Business and Human Rights
U.S.	the United States of America
USPTO	the United States Patent and Trademark Office
U.S. Tax Treaty	Convention between the Netherlands and the U.S. for the avoidance of Double Taxation and the Prevention of Fiscal Evasion with respect to Taxes and Income, dated December 18, 1992 as amended by the protocol of March 8, 2004
UT Agreement	an exclusive in-license with the Board of Regents of the University of Texas System
UT BoR	Board of Regents of the University of Texas System
VBA	Value Based Agreements
V-regions	antibody variable regions
VYVDURA	VYVDURA®
VYVGART	VYVGART® (efgartigimod alfa-fcab)
VYVGART HYTRULO	VYVGART HYTRULO™
VYVGART SC	VYVGART subcutaneous (efgartigimod alfa + hyaluronidase qvfc)
WBCSD	World Business Council for Sustainable Development
we, us or our	argenx SE together with its wholly-owned subsidiaries and, as applicable, its former wholly-owned subsidiaries
WFH	Work from Home
WTT	well-to-tank
WTW	well-to-wheel
Zai Lab	Zai Lab Ltd
Zai Lab Agreement	collaboration agreement with Zai Lab Ltd, relating to an exclusive out-license for the development and commercialization of efgartigimod in Greater China

Contact us via
argenx.com/contact-us

You can find the annual report 2025 online at
reports.argenx.com/2025

